Curis Lifesciences Ltd (CURIS) is currently trading at 176.45 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Curis Lifesciences Limited is an Indian pharmaceutical manufacturer engaged in development, manufacturing, marketing and distribution of tablets, capsules, oral liquids, external preparations and sterile ophthalmic ointments for domestic and international markets, operating a manufacturing facility at Sanand GIDC-II with multi-formulation capacity and customers across Indian pharma marketers and exporters. In FY26 Curis Lifesciences reported revenue of INR 6,062.88 lakh, a 21.16% year‑on‑year increase, with EBITDA of INR 1,141.09 lakh and PAT of INR 691.64 lakh, indicating growth in top-line traction while margins were temporarily compressed by raw material inflation and one-time investments during the year. Management positions FY26 as a year of strategic investments and platform building: the company cites the Uninova Lifesciences acquisition and the Eurosun JV in Nigeria as transformational moves expected to expand international presence and support medium‑term earnings improvement as integration and pricing adjustments take effect. Curis Lifesciences completed an IPO in November 2025 raising INR 27.52 crore and reports installed annual manufacturing capacity metrics—138 crore tablets, 15.75 crore capsules, 1,080 kilolitres of oral liquid and other dosage forms—providing tangible operational scale for revenue growth and export ambitions.

Over the past 52 weeks, Curis Lifesciences Ltd has traded between a low of ₹83.60 and a high of ₹234.75. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Curis Lifesciences Ltd has a market capitalization of approximately 142.65. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Curis Lifesciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 26.61 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 142.65 Cr, Curis Lifesciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Curis Lifesciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Curis Lifesciences Ltd is 26.61. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.